Brief: NFL Biosciences Releases New Results On NFL-101
BRIEF-NFL Biosciences Releases New Results On NFL-101 June 1 (Reuters) - Nfl Biosciences SAS ALNFL.PA:
NFL BIOSCIENCES RELEASES NEW RESULTS ON NFL-101 AND REAFFIRMS ITS PERSONALIZED APPROACH TO SMOKING CESSATION
NFL BIOSCIENCES SAS - NFL-101 EFFICACY ABOUT 30% HIGHER THAN CHAMPIX IN TARGET POPULATION
NFL BIOSCIENCES SAS - NFL-101 SHOWS STATISTICALLY SIGNIFICANT RESULTS VERSUS PLACEBO IN TARGET POPULATION
Source text: ID:nBw93j2HMa
Further company coverage: ALNFL.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nfl Biosciences SAS
See all newsBrief: NFL Biosciences Releases New Results On NFL-101
Brief: NFL Biosciences Receives Funding Of EUR 1.7 Mln From Bpifrance
Brief: NFL Biosciences Raises Over EUR 3 Million
Brief: NFL Biosciences/Themis Medicare: Partnership To Develop NFL-101, Drug Candidate For Smoking Cessation
Brief: NFL Biosciences Launches Phase 2/3 Clinical Trial For Smoking Cessation